Literature DB >> 11108930

Resveratrol inhibits interleukin-6 production in cortical mixed glial cells under hypoxia/hypoglycemia followed by reoxygenation.

M J Wang1, H M Huang, S J Hsieh, K C Jeng, J S Kuo.   

Abstract

Reactive oxygen intermediates (ROIs) are important mediators of a variety of pathological processes, including inflammation and ischemia/reperfusion injury. Cytokines and chemokines are detected at mRNA level in human and animal ischemic brains. This suggests that hypoxia/reoxygenation may induce cytokine production through generation of ROIs. In this study, we investigated the cytokine induction and inhibition by antioxidants in rat cortical mixed glial cells exposed to in vitro ischemia-like insults (hypoxia plus glucose deprivation). The results showed that interleukin-6 (IL-6) mRNA and protein, but not tumor necrosis factor-alpha (TNF-alpha) or interleukin-1beta (IL-1beta), were induced during hypoxia/hypoglycemia followed by reoxygenation in the mixed glial cells. The accumulation of IL-6 mRNA was induced as early as 15 min after hypoxia/hypoglycemia and its level was further increased after subsequent reoxygenation. Among the antioxidants studied, only resveratrol suppressed IL-6 gene expression and protein secretion in mixed glial cultures under hypoxia/hypoglycemia followed by reoxygenation. These findings suggest that resveratrol might be useful in treating ischemic-induced inflammatory processes in stroke.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11108930     DOI: 10.1016/s0165-5728(00)00374-x

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  14 in total

Review 1.  Resveratrol neuroprotection in stroke and traumatic CNS injury.

Authors:  Mary S Lopez; Robert J Dempsey; Raghu Vemuganti
Journal:  Neurochem Int       Date:  2015-08-12       Impact factor: 3.921

2.  Enzymatic Biosynthesis of Novel Resveratrol Glucoside and Glycoside Derivatives.

Authors:  Ramesh Prasad Pandey; Prakash Parajuli; Ju Yong Shin; Jisun Lee; Seul Lee; Young-Soo Hong; Yong Il Park; Joong Su Kim; Jae Kyung Sohng
Journal:  Appl Environ Microbiol       Date:  2014-09-19       Impact factor: 4.792

Review 3.  Metabolic effects of resveratrol: addressing the controversies.

Authors:  Jacob L Bitterman; Jay H Chung
Journal:  Cell Mol Life Sci       Date:  2014-12-30       Impact factor: 9.261

4.  Resveratrol, wine, and atherosclerosis.

Authors:  Kailash Prasad
Journal:  Int J Angiol       Date:  2012-03

Review 5.  Phytochemicals in Ischemic Stroke.

Authors:  Joonki Kim; David Yang-Wei Fann; Raymond Chee Seong Seet; Dong-Gyu Jo; Mark P Mattson; Thiruma V Arumugam
Journal:  Neuromolecular Med       Date:  2016-05-18       Impact factor: 3.843

6.  Temporal profile of cerebrospinal fluid, plasma, and brain interleukin-6 after normothermic fluid-percussion brain injury: effect of secondary hypoxia.

Authors:  Katina Chatzipanteli; Elizabeth Vitarbo; Ofelia F Alonso; Helen M Bramlett; W Dalton Dietrich
Journal:  Ther Hypothermia Temp Manag       Date:  2012-12       Impact factor: 1.286

Review 7.  Neuroprotective properties and mechanisms of resveratrol in in vitro and in vivo experimental cerebral stroke models.

Authors:  Nilendra Singh; Megha Agrawal; Sylvain Doré
Journal:  ACS Chem Neurosci       Date:  2013-06-24       Impact factor: 4.418

8.  Involvement of miR-Let7A in inflammatory response and cell survival/apoptosis regulated by resveratrol in THP-1 macrophage.

Authors:  Juhyun Song; Mira Jun; Mok-Ryeon Ahn; Oh Yoen Kim
Journal:  Nutr Res Pract       Date:  2016-06-16       Impact factor: 1.926

9.  Hypoxia antagonizes glucose deprivation on interleukin 6 expression in an Akt dependent, but HIF-1/2α independent manner.

Authors:  Sung Ji Choi; Ik Jae Shin; Kang-Hoon Je; Eun Kyoung Min; Eun Ji Kim; Hee-Sun Kim; Senyon Choe; Dong-Eog Kim; Dong Kun Lee
Journal:  PLoS One       Date:  2013-03-08       Impact factor: 3.240

Review 10.  Sirtuin deacetylases as therapeutic targets in the nervous system.

Authors:  Brett Langley; Anthony Sauve
Journal:  Neurotherapeutics       Date:  2013-10       Impact factor: 7.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.